Clinical trials: ifosfamide
Pediatric Solid Tumor, Osteosarcoma
B7-H3-Specific Chimeric Antigen Receptor Autologous T-Cell Therapy for Pediatric Patients With Solid Tumors (3CAR)
3CAR is being done to investigate an immunotherapy for patients with solid tumors. It is a Phase I clinical trial evaluating the use of autologous T cells genetically engineered to express B7-H3-CARs for patients ≤ 21 years old…
- Conditions
- Pediatric Solid Tumor, Osteosarcoma, Rhabdomyosarcoma, Neuroblastoma
- Trial name
- NCT04897321
- Testing
- Fludarabine, Cyclophosphamide, MESNA
- Where
- United States
- Volunteers
- 48 people
- Sponsor
- St. Jude Children's Research Hospital
Soft Tissue Sarcomas
The Total Neoadjuvant Therapy for Soft Tissue Sarcoma of the Extremities
For localized soft tissue sarcomas (STS) of the extremities, limb-sparing or conservative surgery with perioperative radiotherapy (RT) is the standard of care. However, several challenges persist.
- Trial name
- NCT06593899
- Testing
- Hypofractionated Radiotherapy, 3 cycles of AI
- Where
- China
- Volunteers
- 51 people
- Sponsor
- Fujian Medical University Union Hospital
Lymphoma
Rituximab and Combination Chemotherapy in Treating Patients With Stage II, Stage III, or Stage IV Diffuse Large B-Cell Non-Hodgkin's Lymphoma
RATIONALE: Monoclonal antibodies, such as rituximab, can block cancer growth in different ways. Some block the ability of cancer cells to grow and spread.
- Trial name
- NCT00274924
- Testing
- filgrastim, rituximab, carboplatin
- Where
- 104 sites in United States
- Volunteers
- 100 people
- Sponsor
- Eastern Cooperative Oncology Group
Transitional Cell Carcinoma
Gemcitabine and Ifosfamide As a Second-Line Systemic Chemotherapy for Cisplatin -Failed Advanced TCC
The purpose of this study is to evaluate the efficacy of Gemcitabine plus Ifosfamind as second line chemotherapy in advanced transitional cell carcinoma in terms of response rate and overall survival .
- Trial name
- NCT00173862
- Testing
- Gemcitabine, Ifosfamide
- Where
- Taiwan
- Volunteers
- 18 people
- Sponsor
- National Taiwan University Hospital
Leukemia, Lymphoma
Rituximab, Chemotherapy, and Filgrastim in Treating Patients With Burkitt's Lymphoma or Burkitt's Leukemia
RATIONALE: Monoclonal antibodies such as rituximab can locate tumor cells and either kill them or deliver tumor-killing substances to them without harming normal cells.
- Trial name
- NCT00039130
- Testing
- filgrastim, rituximab, cyclophosphamide
- Where
- 31 sites in United States
- Volunteers
- 105 people
- Sponsor
- Alliance for Clinical Trials in Oncology
Soft Tissue Sarcoma
PLD and IFO As First-line Treatment for Patients With Advanced or Metastatic STS
This study is designed to evaluate the efficacy and safety of pegylated liposomal doxorubicin (PLD) combined with ifosfamide (IFO) for the first-line treatment of patients with advanced or metastatic soft tissue sarcoma (STS).
- Trial name
- NCT03268772
- Testing
- PLD and IFO
- Where
- China
- Volunteers
- 40 people
- Sponsor
- Fudan University
Lymphoma, Non-Hodgkin, Advanced Stage Diffuse Large B-Cell Non-Hodgkin's Lymphoma
Tailoring Treatment for B Cell Non-hodgkin's Lymphoma Based on PET Scan Results Mid Treatment
The purpose of this study is to assess whether patients who are likely to fail R-CHOP, as predicted by a mid-treatment PET scan, can have an improved outcome if switched to a standard salvage regimen R-ICE (rituximab, ifosfamide…
- Trial name
- LYTPET (NCT00324467)
- Testing
- Cyclophosphamide, Doxorubicin, Vincristine
- Where
- Canada
- Volunteers
- 150 people
- Sponsor
- British Columbia Cancer Agency
Endometrial Cancer, Kidney Cancer
Surgery With or Without Chemotherapy in Treating Patients With Soft Tissue Sarcoma
RATIONALE: Drugs used in chemotherapy use different ways to stop tumor cells from dividing so they stop growing or die. It is not yet known whether giving chemotherapy after surgery is more effective than surgery alone in…
- Conditions
- Endometrial Cancer, Kidney Cancer, Ovarian Cancer, Pheochromocytoma
- Trial name
- NCT00002641
- Testing
- filgrastim, doxorubicin hydrochloride, ifosfamide
- Where
- 45 sites in Austria, Belgium and 11 more
- Volunteers
- 350 people
- Sponsor
- European Organisation for Research and Treatment of Cancer - EORTC
Desmoplastic Small Round Cell Tumor, Ewing Sarcoma of Bone or Soft Tissue
Therapeutic Trial for Patients With Ewing Sarcoma Family of Tumor and Desmoplastic Small Round Cell Tumors
This protocol will study treatment for Ewing sarcoma family of tumors (ESFT) and desmoplastic small round cell tumor (DSRCT). Participants with ESFT will be divided into two treatment groups, A or B, based on tumor…
- Conditions
- Desmoplastic Small Round Cell Tumor, Ewing Sarcoma of Bone or Soft Tissue, Localized Ewing Sarcoma/Peripheral Primitive Neuroectodermal Tumor, Metastatic Ewing Sarcoma/Peripheral Primitive Neuroectodermal Tumor
- Trial name
- NCT01946529
- Testing
- vincristine, doxorubicin, cyclophosphamide
- Where
- United States
- Volunteers
- 24 people
- Sponsor
- St. Jude Children's Research Hospital
Childhood Germ Cell Tumor, Ovarian Cancer
Autologous Peripheral Blood Stem Cell Transplant for Germ Cell Tumors
RATIONALE: Germ cell tumors (GCT) are highly sensitive to chemotherapy such that even with metastatic disease at diagnosis, many patients can be cured.
- Conditions
- Childhood Germ Cell Tumor, Ovarian Cancer, Teratoma
- Trial name
- NCT00432094
- Testing
- carboplatin, etoposide, ifosfamide
- Where
- United States
- Volunteers
- 23 people
- Sponsor
- Masonic Cancer Center, University of Minnesota
Osteosarcoma Recurrent
An Analysis of the Efficacy of High Dose Isofosfamide Through Elastomer
A multicentre, observational, retrospective study to analyse the efficacy of high dose isofosfamide thorugh elastomer in patients with relapsed/ refractory osteosarcoma
- Trial name
- NCT04651569
- Testing
- Observational study
- Where
- 5 sites in Italy
- Volunteers
- 26 people
- Sponsor
- Azienda Ospedaliera Ospedale Infantile Regina Margherita Sant'Anna
Squamous Cell Carcinoma of the Penis, Usual Type
International Penile Advanced Cancer Trial (International Rare Cancers Initiative Study)
This is an international phase III trial, with a Bayesian design, incorporating two sequential randomisations. It efficiently examines a series of questions that routinely arise in the sequencing of treatment.
- Trial name
- InPACT (NCT02305654)
- Testing
- ILND - Inguinal Lymph Node Dissection, Paclitaxel, Ifosfamide
- Where
- 17 sites in United States, United Kingdom
- Volunteers
- 200 people
- Sponsor
- Institute of Cancer Research, United Kingdom
Recurrent Hodgkin Lymphoma, Refractory Hodgkin Lymphoma
Nivolumab, Ifosfamide, Carboplatin, and Etoposide as Second-Line Therapy in Treating Patients With Refractory or Relapsed HL
This phase II trial studies the side effects of nivolumab and to see how well it works when given together with ifosfamide, carboplatin, and etoposide in treating patients with Hodgkin lymphoma that has come back (relapsed) and…
- Trial name
- NCT03016871
- Testing
- Carboplatin, Etoposide, Ifosfamide
- Where
- 4 sites in United States
- Volunteers
- 78 people
- Sponsor
- City of Hope Medical Center
Bladder Cancer, Transitional Cell Cancer of the Renal Pelvis and Ureter
Neoadjuvant Ifosfamide, Doxorubicin, Gemcitabine, and Cisplatin in Treating Patients Who Are Undergoing Radical Cystectomy for Locally Advanced Carcinoma (Cancer) of the Urothelium
RATIONALE: Drugs used in chemotherapy, such as ifosfamide, doxorubicin, gemcitabine, and cisplatin, work in different ways to stop tumor cells from dividing so they stop growing or die.
- Conditions
- Bladder Cancer, Transitional Cell Cancer of the Renal Pelvis and Ureter, Urethral Cancer
- Trial name
- NCT00080795
- Testing
- filgrastim, cisplatin, doxorubicin hydrochloride
- Where
- United States
- Volunteers
- 65 people
- Sponsor
- M.D. Anderson Cancer Center
Cervical Cancer
The Clinical Research of Neoadjuvant Chemotherapy Combined Surgery for Locally Advanced Cervical Cancer
This study is a registration study.The main research: the curative effect of neoadjuvant chemotherapy in the treatment of ⅠB2 and ⅡA2 locally advanced cervical cancer.Research group: the neoadjuvant chemotherapy in combination…
- Trial name
- NCT02471027
- Testing
- Neoadjuvant chemotherapy
- Where
- China
- Volunteers
- 1,000 people
- Sponsor
- Yu mei Wu
Lymphoma, High-grade
Positron Emission Tomography Guided Therapy of Aggressive Non-Hodgkin's Lymphomas
The main purpose of the PETAL trial is to determine whether patients with aggressive non-Hodgkin's lymphomas with a persistently positive PET scan after two cycles of chemotherapy benefit from a change of the treatment protocol.
- Trial name
- PETAL (NCT00554164)
- Testing
- (R-)CHOP protocol, B-ALL protocol
- Where
- Germany
- Volunteers
- 1,073 people
- Sponsor
- University Hospital, Essen
Leukemia
Combination Chemotherapy in Treating Young Adult Patients With Acute Lymphoblastic Leukemia
RATIONALE: Drugs used in chemotherapy work in different ways to stop the growth of cancer cells, either by killing the cells or by stopping them from dividing.
- Trial name
- LAL1308 (NCT01156883)
- Testing
- asparaginase, cyclophosphamide, cytarabine
- Where
- 43 sites in Italy
- Volunteers
- 76 people
- Sponsor
- Gruppo Italiano Malattie EMatologiche dell'Adulto
Metastatic Ewing Sarcoma, Metastatic Malignant Neoplasm in the Bone
Combination Chemotherapy With or Without Ganitumab in Treating Patients With Newly Diagnosed Metastatic Ewing Sarcoma
This randomized phase III trial studies how well combination chemotherapy with or without ganitumab works in treating patients with newly diagnosed Ewing sarcoma that has spread to other parts of the body.
- Conditions
- Metastatic Ewing Sarcoma, Metastatic Malignant Neoplasm in the Bone, Metastatic Malignant Neoplasm in the Bone Marrow, Metastatic Malignant Neoplasm in the Lung
- Trial name
- NCT02306161
- Testing
- Cyclophosphamide, Doxorubicin, Doxorubicin Hydrochloride
- Where
- 314 sites in United States, Canada and 1 more
- Volunteers
- 312 people
- Sponsor
- National Cancer Institute (NCI)
Lymphoma
Bortezomib, Ifosfamide, Carboplatin, and Etoposide, With or Without Rituximab, in Treating Patients With Relapsed or Refractory AIDS-Related Non-Hodgkin Lymphoma
RATIONALE: Bortezomib may stop the growth of cancer cells by blocking some of the enzymes needed for cell growth and by blocking blood flow to the cancer.
- Trial name
- NCT00598169
- Testing
- rituximab, bortezomib, carboplatin
- Where
- 17 sites in United States
- Volunteers
- 23 people
- Sponsor
- AIDS Malignancy Consortium
Recurrent Classic Hodgkin Lymphoma, Refractory Classic Hodgkin Lymphoma
A Trial Comparing Chemotherapy Versus Novel Immune Checkpoint Inhibitor (Pembrolizumab) Plus Chemotherapy in Treating Relapsed/Refractory Classical Hodgkin Lymphoma
This phase III trial compares chemotherapy versus an immune checkpoint inhibitor drug called pembrolizumab plus chemotherapy in treating patients with classical Hodgkin lymphoma that has come back (relapsed) or that does not…
- Trial name
- NCT05711628
- Testing
- Autologous Hematopoietic Stem Cell Transplantation, Bendamustine, Brentuximab Vedotin
- Sponsor
- National Cancer Institute (NCI)